ARASENS: darolutamide added to androgen deprivation and docetaxel in metastatic hormone-sensitive prostate cancer
Adding the androgen receptor inhibitor darolutamide to hormone therapy and docetaxel chemotherapy cut deaths by a third in metastatic hormone-sensitive prostate cancer, establishing triplet therapy for men fit for chemotherapy.
Overview
Phase 3 placebo-controlled trial of 1,306 men with metastatic hormone-sensitive prostate cancer randomised to androgen deprivation plus docetaxel with darolutamide or placebo.
Four-year overall survival was 62.7 versus 50.4 percent (hazard ratio 0.68), with delayed castration resistance, pain progression and skeletal events, and no meaningful increase in toxicity beyond docetaxel; benefit was seen in both high- and low-volume disease.
- Four-year overall survival 62.7 percent vs 50.4 percent; hazard ratio 0.68.
- Time to castration-resistant disease hazard ratio 0.36.
Triplet therapy with darolutamide is a standard for fit men with metastatic hormone-sensitive prostate cancer, particularly high-volume disease; PEACE-1 showed the same with abiraterone.
- No arm of androgen deprivation plus darolutamide without docetaxel, so the contribution of docetaxel is unproven.
- Most patients had high-volume disease.
Similar pages
not linked directly; found by shared links- TrialARANOTE
Shares Darolutamide, Metastatic hormone-sensitive prostate cancer.
- TrialTulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in
Shares Darolutamide, Metastatic hormone-sensitive prostate cancer.
- Key paperCHAARTED: chemohormonal therapy in metastatic hormone-sensitive prostate cancer
Shares Metastatic hormone-sensitive prostate cancer, New England Journal of Medicine.
- Key paperARAMIS: darolutamide in non-metastatic castration-resistant prostate cancer
- Key paperLATITUDE: abiraterone plus prednisone in newly diagnosed high-risk metastatic castration-sensitive prostate cancer
Shares Metastatic hormone-sensitive prostate cancer, New England Journal of Medicine.
- TermDisease volume (CHAARTED high-volume versus low-volume) and LATITUDE risk
Shares Darolutamide, Metastatic hormone-sensitive prostate cancer.
- Key paperSTAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer
Shares Metastatic hormone-sensitive prostate cancer, New England Journal of Medicine.